- Integumen said it would present its breakthough results on human skin cloning swabs at the Microbiome AI conference in San Diego, California, USA, later today.

Labskin scientists cloned 16 swabs of skin from the cheeks of healthy volunteers into 54 Labskin test subjects to allow sequencing of microbial DNA for the identification and quantification of the bacterial microbiome isolated and pooled together. The live bacteria, virus and fungi (microbiota) was sustained on all 54 test subjects for up to 14 days in the Labskin laboratories in York, UK, the company said.

'The results of this study validate Labskin's ability to test multiple clinical trial and skincare products in parallel, on the cloned human skin microbiome, that is as close to the original microbiome of a human test subject, without the need for human volunteers after initial cloning takes place,' the company said. 'This allows multiple skincare products or topical drug samples to be tested on the same subject, at the same time, thus substantially reducing development time, clinical error and clinical trial supervision costs.'

At 9:10am: [LON:SKIN] Integumen Plc Ord 1p share price was +0.02p at 1.99p

Story provided by